Carvolix is a French medical technology company founded by Truffle Capital, developing robotic and biomimetic technologies for the treatment of structural heart disease and stroke. Its portfolio includes AI and imaging driven mini robots designed to enable interventional cardiologists to perform complex procedures, as well as biomimetic heart valves. The company has both commercial and clinical stage programmes and aims to build a global position in these large and growing markets.